We observed that lung adenocarcinoma patients with higher levels of the therapy-induced survival signature markers ABCG2, FOS, MAPK13, and NFE2L2 showed a significant higher overall survival of 86, 73, 75.43, and 80 months, respectively (HR = 0.8, p = 0.00017; HR = 0.87, p = 0.023; HR = 0.85, p = 0.0055; HR = 0.84, p = 0.0053), compared to the overall survival of 61, 63.03, 64, and 62 months of patients with low expression levels (Figure 7A, upper panels). The gene discussed is MAPK13; the disease is lung adenocarcinoma.